High-plex proteomics translates information about specific protein abundance into corresponding DNA abundance. In doing so, it effectively mirrors the approach used in transcriptomics. However, most existing high-plex proteomics systems have taken a bottom-up approach, identifying probes for individual proteins one at a time, and gradually building a probe array from these components.

At NeoVentures Biotechnology Europe, we are the only ones to have taken a more powerful and innovative approach by working from the top down. Rather than building probe arrays one protein at a time, we have instead developed a comprehensive platform, called the Aptamarker Platform, based on the application of the same 268 million Aptamarkers to every sample. Through this standardized and scalable method, we are able to characterize differential binding of these probes to potential biomarkers in biological fluids or tissues by leveraging next-generation sequencing (NGS) analysis. As a result, our approach offers a more efficient and reproducible path to high-plex proteomic profiling.

There are several advantages to our top-down approach:

• Greater depth of coverage 268 million probes versus several thousand with other platforms.
• Ease of use, we do not build arrays, and there is no need for specialized equipment to perform the Aptamarker analysis.
• High reproducibility, we are not using polyclonal antibodies.
• Capacity to characterize non-canonical in addition to canonical forms of proteins (post-translational modifications)
• Not limited by reference to human proteins.
• Clear path to Dx applications